Prednisone osteoporosis with

Prednisone -corticosteroid -leukocytosis -nausea and vomiting indigestion -anorexia or increased appetite -CNS effects (depression, anxiety, euphoria, insomnia, psychosis, confusion) -fluid retention -hyperglycemia -osteoporosis -acne -adrenal insufficiency with prolonged use... 

Guidelines for managing corticosteroid-induced osteoporosis recommend measuring BMD at the beginning of chronic therapy (prednisone 5 mg or more daily or equivalent for at least 6 months) and followup monitoring with DXA in 6 to 12 months. BMD should be measured in patients taking chronic therapy whose baseline values were not obtained. 

Fluoride is a potent stimulator of trabecular bone formation. Sodium monofluorophosphate was given to 48 patients with osteoporosis due to glucocorticoids (more than 10 mg of prednisone equivalents/day). Patients were randomly allocated to 1 g of calcium carbonate (control) or 200 mg of sodium monofluorophosphate plus 1 g of... 

Certaiu medicatious have beeu associated with au iucrease iu osteoporosis risk, particularly steroids and anticonvulsants. Steroid-induced osteoporosis arises due to use of glucocorticoids, analogous to Cushing s syndrome, and involving mainly the axial skeleton prednisone... 

A variety of debilitating diseases, such as rheumatoid arthritis, inflammatory myopathies, cancers, and a variety of immunological diseases are treated with the classic synthetic glucocorticoids, dexamethasone, and prednisone. However, long-term treatment with these drugs often leads to serious side effects such as fat redistribution, diabetes, vascular necrosis, and osteoporosis. There is currently an intense effort to identify new small molecules that are able to differentially modulate GR to retain the beneficial effects of glucocorticoids and reduce the incidence of unwanted side effects [10]. 

Rizzato G, Tosi G, Mella C, et al. Prednisone-induced bone loss in sarcoidosis a risk especially frequent in postmenopausal women. Sarcoidosis 1988 5 93 98. Gallacher SJ, Fenner JA, Anderson K, et al. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease an open pilot study. Thorax 1992 47 932-936. 

---